Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
free of cerebral metastasis survival
5 years
No
Yazid BELKACEMI, MD
Principal Investigator
y-belkacemi@o-lambret.fr
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
TSARINE 0602
NCT01613482
October 2007
October 2012
Name | Location |
---|